473 related articles for article (PubMed ID: 15274390)
1. Peroxisome proliferator activated receptor gamma immunohistochemical expression in human papillary thyroid carcinoma tissues. Possible relationship to lymph node metastasis.
Galusca B; Dumollard JM; Chambonniere ML; Germain N; Prades JM; Péoc'h M; Estour B
Anticancer Res; 2004; 24(3b):1993-7. PubMed ID: 15274390
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma expression in follicular-patterned thyroid lesions. Caveats for the use of immunohistochemical studies.
Gustafson KS; LiVolsi VA; Furth EE; Pasha TL; Putt ME; Baloch ZW
Am J Clin Pathol; 2003 Aug; 120(2):175-81. PubMed ID: 12931546
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases.
Yu XM; Lo CY; Chan WF; Lam KY; Leung P; Luk JM
Clin Cancer Res; 2005 Nov; 11(22):8063-9. PubMed ID: 16299237
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas.
Aldred MA; Morrison C; Gimm O; Hoang-Vu C; Krause U; Dralle H; Jhiang S; Eng C
Oncogene; 2003 May; 22(22):3412-6. PubMed ID: 12776192
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
[TBL] [Abstract][Full Text] [Related]
6. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis.
Yasuoka H; Kodama R; Hirokawa M; Takamura Y; Miyauchi A; Sanke T; Nakamura Y
BMC Cancer; 2008 Sep; 8():274. PubMed ID: 18826577
[TBL] [Abstract][Full Text] [Related]
8. Hybrid thyroid carcinoma with a coarse chromatin pattern and nuclear features of papillary thyroid carcinoma.
Mai KT; Bokhary R; Yazdi HM; Thomas J
Pathol Res Pract; 2002; 198(4):253-60. PubMed ID: 12049333
[TBL] [Abstract][Full Text] [Related]
9. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma.
Machens A; Holzhausen HJ; Dralle H
Cancer; 2005 Jun; 103(11):2269-73. PubMed ID: 15856429
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm.
Tabriz HM; Adabi Kh; Lashkari A; Heshmat R; Haghpanah V; Larijani B; Tavangar SM
Pathol Res Pract; 2009; 205(2):83-7. PubMed ID: 18996649
[TBL] [Abstract][Full Text] [Related]
11. Altered chemokine receptor expression in papillary thyroid cancer.
González HE; Leiva A; Tobar H; Böhmwald K; Tapia G; Torres J; Mosso LM; Bueno SM; Gonzalez P; Kalergis AM; Riedel CA
Thyroid; 2009 Sep; 19(9):957-65. PubMed ID: 19731977
[TBL] [Abstract][Full Text] [Related]
12. Differentiated thyroid carcinomas with vascular invasion: a comparative study of follicular, Hürthle cell and papillary thyroid carcinoma.
Mai KT; Khanna P; Yazdi HM; Perkins DG; Veinot JP; Thomas J; Lamba M; Nair BD
Pathology; 2002 Jun; 34(3):239-44. PubMed ID: 12109784
[TBL] [Abstract][Full Text] [Related]
13. Expression of cell-cycle regulators (cyclin D1, cyclin E, p27kip1, p57kip2) in papillary thyroid carcinoma.
Lee SH; Lee JK; Jin SM; Lee KC; Sohn JH; Chae SW; Kim DH
Otolaryngol Head Neck Surg; 2010 Mar; 142(3):332-7. PubMed ID: 20172376
[TBL] [Abstract][Full Text] [Related]
14. Retinoblastoma expression in thyroid neoplasms.
Anwar F; Emond MJ; Schmidt RA; Hwang HC; Bronner MP
Mod Pathol; 2000 May; 13(5):562-9. PubMed ID: 10824929
[TBL] [Abstract][Full Text] [Related]
15. Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Hum Pathol; 2008 Nov; 39(11):1656-63. PubMed ID: 18657294
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of transketolase-like-1 in papillary thyroid carcinomas smaller than 1.5 cm in diameter is associated with lymph-node metastases.
Zerilli M; Amato MC; Martorana A; Cabibi D; Coy JF; Cappello F; Pompei G; Russo A; Giordano C; Rodolico V
Cancer; 2008 Sep; 113(5):936-44. PubMed ID: 18615628
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms.
Huang SM; Lee JC; Wu TJ; Chow NH
World J Surg; 2001 Mar; 25(3):302-6. PubMed ID: 11343180
[TBL] [Abstract][Full Text] [Related]
18. Intercellular adhesion molecule-1 (ICAM-1) is upregulated in aggressive papillary thyroid carcinoma.
Buitrago D; Keutgen XM; Crowley M; Filicori F; Aldailami H; Hoda R; Liu YF; Hoda RS; Scognamiglio T; Jin M; Fahey TJ; Zarnegar R
Ann Surg Oncol; 2012 Mar; 19(3):973-80. PubMed ID: 21879273
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-receptor protein in thyroid neoplasms. An immunohistochemical analysis of papillary carcinoma, follicular carcinoma, and follicular adenoma.
Diaz NM; Mazoujian G; Wick MR
Arch Pathol Lab Med; 1991 Dec; 115(12):1203-7. PubMed ID: 1768209
[TBL] [Abstract][Full Text] [Related]
20. Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis.
Ying H; Suzuki H; Zhao L; Willingham MC; Meltzer P; Cheng SY
Cancer Res; 2003 Sep; 63(17):5274-80. PubMed ID: 14500358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]